nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.0513	0.09	CbGbCtD
Duloxetine—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.0482	0.0846	CbGbCtD
Duloxetine—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.0482	0.0846	CbGbCtD
Duloxetine—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.0436	0.0765	CbGbCtD
Duloxetine—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0423	0.0741	CbGbCtD
Duloxetine—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0397	0.0697	CbGbCtD
Duloxetine—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0397	0.0697	CbGbCtD
Duloxetine—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.0366	0.0641	CbGbCtD
Duloxetine—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0359	0.063	CbGbCtD
Duloxetine—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0359	0.063	CbGbCtD
Duloxetine—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.0331	0.058	CbGbCtD
Duloxetine—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.031	0.0544	CbGbCtD
Duloxetine—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.0301	0.0528	CbGbCtD
Duloxetine—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.0272	0.0478	CbGbCtD
Duloxetine—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.0272	0.0478	CbGbCtD
Duloxetine—NPY1R—nerve—acquired immunodeficiency syndrome	0.00821	0.131	CbGeAlD
Duloxetine—SLC6A3—nerve—acquired immunodeficiency syndrome	0.00345	0.055	CbGeAlD
Duloxetine—SLC6A2—nerve—acquired immunodeficiency syndrome	0.00279	0.0444	CbGeAlD
Duloxetine—SLC6A4—blood plasma—acquired immunodeficiency syndrome	0.00239	0.0381	CbGeAlD
Duloxetine—NPY1R—blood—acquired immunodeficiency syndrome	0.00227	0.0362	CbGeAlD
Duloxetine—NPY1R—vagina—acquired immunodeficiency syndrome	0.00211	0.0336	CbGeAlD
Duloxetine—NPY1R—lung—acquired immunodeficiency syndrome	0.00199	0.0317	CbGeAlD
Duloxetine—NPY1R—nervous system—acquired immunodeficiency syndrome	0.00185	0.0294	CbGeAlD
Duloxetine—NPY1R—central nervous system—acquired immunodeficiency syndrome	0.00178	0.0283	CbGeAlD
Duloxetine—HTR2A—nerve—acquired immunodeficiency syndrome	0.00167	0.0267	CbGeAlD
Duloxetine—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.00162	0.0258	CbGeAlD
Duloxetine—HTR2A—endothelium—acquired immunodeficiency syndrome	0.00143	0.0227	CbGeAlD
Duloxetine—NPY1R—brain—acquired immunodeficiency syndrome	0.00141	0.0225	CbGeAlD
Duloxetine—NPY1R—lymph node—acquired immunodeficiency syndrome	0.00136	0.0217	CbGeAlD
Duloxetine—HTR6—nervous system—acquired immunodeficiency syndrome	0.0013	0.0207	CbGeAlD
Duloxetine—HTR2A—blood plasma—acquired immunodeficiency syndrome	0.00127	0.0202	CbGeAlD
Duloxetine—HTR6—central nervous system—acquired immunodeficiency syndrome	0.00125	0.0199	CbGeAlD
Duloxetine—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.00115	0.0184	CbGeAlD
Duloxetine—HTR6—brain—acquired immunodeficiency syndrome	0.000993	0.0158	CbGeAlD
Duloxetine—SLC6A3—spinal cord—acquired immunodeficiency syndrome	0.000922	0.0147	CbGeAlD
Duloxetine—SLC6A4—digestive system—acquired immunodeficiency syndrome	0.000921	0.0147	CbGeAlD
Duloxetine—HTR2C—spinal cord—acquired immunodeficiency syndrome	0.000891	0.0142	CbGeAlD
Duloxetine—SLC6A4—blood—acquired immunodeficiency syndrome	0.000877	0.014	CbGeAlD
Duloxetine—SLC6A4—spinal cord—acquired immunodeficiency syndrome	0.000845	0.0135	CbGeAlD
Duloxetine—SLC6A3—lung—acquired immunodeficiency syndrome	0.000839	0.0134	CbGeAlD
Duloxetine—SLC6A3—nervous system—acquired immunodeficiency syndrome	0.000777	0.0124	CbGeAlD
Duloxetine—SLC6A4—lung—acquired immunodeficiency syndrome	0.000769	0.0122	CbGeAlD
Duloxetine—HTR2C—nervous system—acquired immunodeficiency syndrome	0.000751	0.012	CbGeAlD
Duloxetine—SLC6A3—central nervous system—acquired immunodeficiency syndrome	0.000748	0.0119	CbGeAlD
Duloxetine—HTR2C—central nervous system—acquired immunodeficiency syndrome	0.000723	0.0115	CbGeAlD
Duloxetine—SLC6A4—nervous system—acquired immunodeficiency syndrome	0.000712	0.0113	CbGeAlD
Duloxetine—HTR2A—retina—acquired immunodeficiency syndrome	0.000694	0.011	CbGeAlD
Duloxetine—SLC6A4—central nervous system—acquired immunodeficiency syndrome	0.000685	0.0109	CbGeAlD
Duloxetine—SLC6A2—lung—acquired immunodeficiency syndrome	0.000677	0.0108	CbGeAlD
Duloxetine—NPY1R—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.000658	0.015	CbGpPWpGaD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000646	0.0147	CbGpPWpGaD
Duloxetine—SLC6A2—nervous system—acquired immunodeficiency syndrome	0.000627	0.00998	CbGeAlD
Duloxetine—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.000623	0.00992	CbGeAlD
Duloxetine—SLC6A2—central nervous system—acquired immunodeficiency syndrome	0.000603	0.00961	CbGeAlD
Duloxetine—NPY1R—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.000595	0.0135	CbGpPWpGaD
Duloxetine—SLC6A3—brain—acquired immunodeficiency syndrome	0.000594	0.00945	CbGeAlD
Duloxetine—CYP1A2—blood—acquired immunodeficiency syndrome	0.000594	0.00945	CbGeAlD
Duloxetine—HTR2C—brain—acquired immunodeficiency syndrome	0.000574	0.00914	CbGeAlD
Duloxetine—NPY1R—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000559	0.0127	CbGpPWpGaD
Duloxetine—NPY1R—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000559	0.0127	CbGpPWpGaD
Duloxetine—SLC6A4—brain—acquired immunodeficiency syndrome	0.000544	0.00866	CbGeAlD
Duloxetine—NPY1R—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000544	0.0124	CbGpPWpGaD
Duloxetine—CYP1A2—lung—acquired immunodeficiency syndrome	0.00052	0.00828	CbGeAlD
Duloxetine—NPY1R—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000502	0.0114	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000492	0.0112	CbGpPWpGaD
Duloxetine—HTR2A—digestive system—acquired immunodeficiency syndrome	0.000487	0.00775	CbGeAlD
Duloxetine—SLC6A2—brain—acquired immunodeficiency syndrome	0.000479	0.00763	CbGeAlD
Duloxetine—NPY1R—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000472	0.0107	CbGpPWpGaD
Duloxetine—NPY1R—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000472	0.0107	CbGpPWpGaD
Duloxetine—NPY1R—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000466	0.0106	CbGpPWpGaD
Duloxetine—HTR2A—blood—acquired immunodeficiency syndrome	0.000464	0.00739	CbGeAlD
Duloxetine—SLC6A2—lymph node—acquired immunodeficiency syndrome	0.000463	0.00737	CbGeAlD
Duloxetine—NPY1R—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00046	0.0105	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Other—ACKR1—acquired immunodeficiency syndrome	0.000452	0.0103	CbGpPWpGaD
Duloxetine—HTR2A—spinal cord—acquired immunodeficiency syndrome	0.000447	0.00712	CbGeAlD
Duloxetine—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000444	0.00706	CbGeAlD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000441	0.01	CbGpPWpGaD
Duloxetine—NPY1R—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000438	0.00997	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000435	0.0099	CbGpPWpGaD
Duloxetine—HTR2A—vagina—acquired immunodeficiency syndrome	0.00043	0.00685	CbGeAlD
Duloxetine—NPY1R—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000425	0.00968	CbGpPWpGaD
Duloxetine—CYP2D6—blood—acquired immunodeficiency syndrome	0.000423	0.00673	CbGeAlD
Duloxetine—HTR2A—lung—acquired immunodeficiency syndrome	0.000407	0.00648	CbGeAlD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000399	0.00908	CbGpPWpGaD
Duloxetine—NPY1R—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.000383	0.00873	CbGpPWpGaD
Duloxetine—HTR2A—nervous system—acquired immunodeficiency syndrome	0.000377	0.006	CbGeAlD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000375	0.00854	CbGpPWpGaD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000375	0.00854	CbGpPWpGaD
Duloxetine—HTR2A—central nervous system—acquired immunodeficiency syndrome	0.000363	0.00577	CbGeAlD
Duloxetine—NPY1R—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000359	0.00817	CbGpPWpGaD
Duloxetine—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000343	0.00546	CbGeAlD
Duloxetine—NPY1R—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000336	0.00765	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000331	0.00754	CbGpPWpGaD
Duloxetine—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.00033	0.00526	CbGeAlD
Duloxetine—NPY1R—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000323	0.00736	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00032	0.00729	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000304	0.00692	CbGpPWpGaD
Duloxetine—NPY1R—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.0003	0.00683	CbGpPWpGaD
Duloxetine—HTR2A—brain—acquired immunodeficiency syndrome	0.000288	0.00458	CbGeAlD
Duloxetine—NPY1R—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000286	0.0065	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000286	0.0065	CbGpPWpGaD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000285	0.0065	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000279	0.00635	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000278	0.00633	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000272	0.00619	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000263	0.006	CbGpPWpGaD
Duloxetine—SLC6A4—Monoamine Transport—TNF—acquired immunodeficiency syndrome	0.000263	0.00598	CbGpPWpGaD
Duloxetine—CYP2D6—brain—acquired immunodeficiency syndrome	0.000262	0.00418	CbGeAlD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000257	0.00585	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000252	0.00574	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000244	0.00555	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000238	0.00542	CbGpPWpGaD
Duloxetine—SLC6A2—Monoamine Transport—TNF—acquired immunodeficiency syndrome	0.000226	0.00515	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000217	0.00495	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000212	0.00482	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000201	0.00457	CbGpPWpGaD
Duloxetine—SLC6A3—Monoamine Transport—TNF—acquired immunodeficiency syndrome	0.0002	0.00456	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000196	0.00446	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	0.000194	0.00443	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000194	0.00442	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000181	0.00413	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000175	0.00399	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000172	0.00392	CbGpPWpGaD
Duloxetine—HTR6—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000172	0.00391	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000172	0.00391	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00017	0.00387	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000168	0.00383	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000165	0.00375	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000165	0.00375	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Other—CCR5—acquired immunodeficiency syndrome	0.000163	0.00371	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000163	0.0037	CbGpPWpGaD
Duloxetine—HTR6—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000161	0.00368	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000161	0.00367	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000161	0.00367	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000156	0.00355	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000152	0.00347	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000149	0.00339	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000148	0.00336	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000147	0.00335	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000147	0.00334	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000147	0.00334	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000138	0.00315	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000138	0.00315	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000134	0.00304	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000128	0.00292	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000126	0.00288	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000125	0.00285	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000124	0.00282	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000123	0.0028	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000121	0.00275	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.00012	0.00273	CbGpPWpGaD
Duloxetine—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.00012	0.000371	CcSEcCtD
Duloxetine—Ill-defined disorder—Lamivudine—acquired immunodeficiency syndrome	0.00012	0.00037	CcSEcCtD
Duloxetine—Chest pain—Ritonavir—acquired immunodeficiency syndrome	0.000119	0.00037	CcSEcCtD
Duloxetine—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.000119	0.00037	CcSEcCtD
Duloxetine—Myalgia—Ritonavir—acquired immunodeficiency syndrome	0.000119	0.00037	CcSEcCtD
Duloxetine—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000119	0.000369	CcSEcCtD
Duloxetine—Anaemia—Lamivudine—acquired immunodeficiency syndrome	0.000119	0.000369	CcSEcCtD
Duloxetine—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000119	0.000369	CcSEcCtD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000119	0.00271	CbGpPWpGaD
Duloxetine—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000119	0.000368	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000119	0.000367	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000118	0.000366	CcSEcCtD
Duloxetine—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000118	0.000366	CcSEcCtD
Duloxetine—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000118	0.000366	CcSEcCtD
Duloxetine—Anorexia—Delavirdine—acquired immunodeficiency syndrome	0.000118	0.000366	CcSEcCtD
Duloxetine—Discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000118	0.000366	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000118	0.000365	CcSEcCtD
Duloxetine—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000118	0.000365	CcSEcCtD
Duloxetine—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.000118	0.000365	CcSEcCtD
Duloxetine—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000117	0.000363	CcSEcCtD
Duloxetine—Pain—Indinavir—acquired immunodeficiency syndrome	0.000117	0.000363	CcSEcCtD
Duloxetine—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000117	0.000363	CcSEcCtD
Duloxetine—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000117	0.000362	CcSEcCtD
Duloxetine—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000117	0.000362	CcSEcCtD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	0.000117	0.00266	CbGpPWpGaD
Duloxetine—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000117	0.000362	CcSEcCtD
Duloxetine—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000117	0.000361	CcSEcCtD
Duloxetine—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000116	0.000361	CcSEcCtD
Duloxetine—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000116	0.000361	CcSEcCtD
Duloxetine—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000116	0.00036	CcSEcCtD
Duloxetine—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.000116	0.00036	CcSEcCtD
Duloxetine—Malaise—Lamivudine—acquired immunodeficiency syndrome	0.000116	0.00036	CcSEcCtD
Duloxetine—HTR2A—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000116	0.00264	CbGpPWpGaD
Duloxetine—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000116	0.000359	CcSEcCtD
Duloxetine—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000116	0.000359	CcSEcCtD
Duloxetine—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.000116	0.000359	CcSEcCtD
Duloxetine—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000116	0.000358	CcSEcCtD
Duloxetine—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.000115	0.000358	CcSEcCtD
Duloxetine—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	0.000115	0.000357	CcSEcCtD
Duloxetine—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000115	0.000356	CcSEcCtD
Duloxetine—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.000115	0.000356	CcSEcCtD
Duloxetine—Chest pain—Saquinavir—acquired immunodeficiency syndrome	0.000115	0.000356	CcSEcCtD
Duloxetine—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.000115	0.000356	CcSEcCtD
Duloxetine—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000115	0.000355	CcSEcCtD
Duloxetine—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000115	0.000355	CcSEcCtD
Duloxetine—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000114	0.000354	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000114	0.000354	CcSEcCtD
Duloxetine—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000114	0.000353	CcSEcCtD
Duloxetine—Discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000114	0.000352	CcSEcCtD
Duloxetine—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.000113	0.000351	CcSEcCtD
Duloxetine—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000113	0.00035	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000113	0.000349	CcSEcCtD
Duloxetine—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000113	0.000349	CcSEcCtD
Duloxetine—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000113	0.000349	CcSEcCtD
Duloxetine—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000112	0.000348	CcSEcCtD
Duloxetine—Cough—Lamivudine—acquired immunodeficiency syndrome	0.000112	0.000348	CcSEcCtD
Duloxetine—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000112	0.000348	CcSEcCtD
Duloxetine—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000112	0.000348	CcSEcCtD
Duloxetine—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	0.000112	0.000347	CcSEcCtD
Duloxetine—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000112	0.000347	CcSEcCtD
Duloxetine—HTR6—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000112	0.00255	CbGpPWpGaD
Duloxetine—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000112	0.000347	CcSEcCtD
Duloxetine—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000112	0.000347	CcSEcCtD
Duloxetine—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.000112	0.000346	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000112	0.000346	CcSEcCtD
Duloxetine—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.000112	0.000346	CcSEcCtD
Duloxetine—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000112	0.000346	CcSEcCtD
Duloxetine—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000112	0.000346	CcSEcCtD
Duloxetine—NPY1R—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000111	0.00254	CbGpPWpGaD
Duloxetine—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000111	0.000345	CcSEcCtD
Duloxetine—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.000111	0.000344	CcSEcCtD
Duloxetine—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.000111	0.000344	CcSEcCtD
Duloxetine—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000111	0.000343	CcSEcCtD
Duloxetine—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000111	0.000343	CcSEcCtD
Duloxetine—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000111	0.000343	CcSEcCtD
Duloxetine—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000111	0.000343	CcSEcCtD
Duloxetine—HTR6—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000111	0.00252	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000111	0.00252	CbGpPWpGaD
Duloxetine—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000111	0.000342	CcSEcCtD
Duloxetine—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.00011	0.000342	CcSEcCtD
Duloxetine—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.00011	0.000341	CcSEcCtD
Duloxetine—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.00011	0.000341	CcSEcCtD
Duloxetine—Headache—Nevirapine—acquired immunodeficiency syndrome	0.00011	0.000341	CcSEcCtD
Duloxetine—NPY1R—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.00011	0.0025	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00011	0.0025	CbGpPWpGaD
Duloxetine—Myalgia—Lamivudine—acquired immunodeficiency syndrome	0.00011	0.00034	CcSEcCtD
Duloxetine—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.00011	0.00034	CcSEcCtD
Duloxetine—Chest pain—Lamivudine—acquired immunodeficiency syndrome	0.00011	0.00034	CcSEcCtD
Duloxetine—Infection—Saquinavir—acquired immunodeficiency syndrome	0.00011	0.000339	CcSEcCtD
Duloxetine—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000109	0.000339	CcSEcCtD
Duloxetine—Anorexia—Ritonavir—acquired immunodeficiency syndrome	0.000109	0.000338	CcSEcCtD
Duloxetine—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000109	0.000338	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000109	0.000337	CcSEcCtD
Duloxetine—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.000109	0.000337	CcSEcCtD
Duloxetine—HTR2A—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000109	0.00247	CbGpPWpGaD
Duloxetine—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000108	0.000336	CcSEcCtD
Duloxetine—Discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000108	0.000336	CcSEcCtD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000108	0.00247	CbGpPWpGaD
Duloxetine—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000108	0.000335	CcSEcCtD
Duloxetine—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000108	0.000335	CcSEcCtD
Duloxetine—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000108	0.000335	CcSEcCtD
Duloxetine—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000108	0.000335	CcSEcCtD
Duloxetine—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	0.000108	0.000334	CcSEcCtD
Duloxetine—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000108	0.000334	CcSEcCtD
Duloxetine—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000108	0.000333	CcSEcCtD
Duloxetine—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000107	0.000332	CcSEcCtD
Duloxetine—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000107	0.000332	CcSEcCtD
Duloxetine—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000107	0.000332	CcSEcCtD
Duloxetine—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000107	0.000332	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000107	0.000331	CcSEcCtD
Duloxetine—Rash—Stavudine—acquired immunodeficiency syndrome	0.000107	0.000331	CcSEcCtD
Duloxetine—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000107	0.000331	CcSEcCtD
Duloxetine—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000107	0.000331	CcSEcCtD
Duloxetine—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.000107	0.00033	CcSEcCtD
Duloxetine—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000107	0.00033	CcSEcCtD
Duloxetine—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000107	0.00033	CcSEcCtD
Duloxetine—Headache—Stavudine—acquired immunodeficiency syndrome	0.000106	0.000329	CcSEcCtD
Duloxetine—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000106	0.000329	CcSEcCtD
Duloxetine—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.000106	0.000328	CcSEcCtD
Duloxetine—Pain—Delavirdine—acquired immunodeficiency syndrome	0.000106	0.000328	CcSEcCtD
Duloxetine—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000106	0.000328	CcSEcCtD
Duloxetine—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000106	0.000328	CcSEcCtD
Duloxetine—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000106	0.000327	CcSEcCtD
Duloxetine—HTR6—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000105	0.0024	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000105	0.0024	CbGpPWpGaD
Duloxetine—Rash—Abacavir—acquired immunodeficiency syndrome	0.000105	0.000326	CcSEcCtD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000105	0.0024	CbGpPWpGaD
Duloxetine—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000105	0.000326	CcSEcCtD
Duloxetine—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000105	0.000326	CcSEcCtD
Duloxetine—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.000105	0.000326	CcSEcCtD
Duloxetine—Anorexia—Saquinavir—acquired immunodeficiency syndrome	0.000105	0.000325	CcSEcCtD
Duloxetine—Headache—Abacavir—acquired immunodeficiency syndrome	0.000105	0.000324	CcSEcCtD
Duloxetine—Infection—Lamivudine—acquired immunodeficiency syndrome	0.000104	0.000324	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000104	0.000323	CcSEcCtD
Duloxetine—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000104	0.000323	CcSEcCtD
Duloxetine—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000104	0.000323	CcSEcCtD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000104	0.00237	CbGpPWpGaD
Duloxetine—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.000104	0.000321	CcSEcCtD
Duloxetine—Shock—Lamivudine—acquired immunodeficiency syndrome	0.000103	0.00032	CcSEcCtD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000103	0.00235	CbGpPWpGaD
Duloxetine—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000103	0.000319	CcSEcCtD
Duloxetine—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	0.000103	0.000319	CcSEcCtD
Duloxetine—HTR6—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000103	0.00234	CbGpPWpGaD
Duloxetine—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.000103	0.000319	CcSEcCtD
Duloxetine—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.000103	0.000318	CcSEcCtD
Duloxetine—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000102	0.000317	CcSEcCtD
Duloxetine—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000102	0.000317	CcSEcCtD
Duloxetine—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000102	0.000316	CcSEcCtD
Duloxetine—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.000102	0.000316	CcSEcCtD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000102	0.00232	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000102	0.00232	CbGpPWpGaD
Duloxetine—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000102	0.000315	CcSEcCtD
Duloxetine—NPY1R—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000102	0.00232	CbGpPWpGaD
Duloxetine—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.000102	0.000315	CcSEcCtD
Duloxetine—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000101	0.000314	CcSEcCtD
Duloxetine—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000101	0.000313	CcSEcCtD
Duloxetine—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000101	0.000313	CcSEcCtD
Duloxetine—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000101	0.000312	CcSEcCtD
Duloxetine—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000101	0.000312	CcSEcCtD
Duloxetine—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000101	0.000312	CcSEcCtD
Duloxetine—NPY1R—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.0001	0.00229	CbGpPWpGaD
Duloxetine—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.0001	0.000311	CcSEcCtD
Duloxetine—HTR6—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.0001	0.00228	CbGpPWpGaD
Duloxetine—Anorexia—Lamivudine—acquired immunodeficiency syndrome	0.0001	0.00031	CcSEcCtD
Duloxetine—Insomnia—Saquinavir—acquired immunodeficiency syndrome	9.97e-05	0.000309	CcSEcCtD
Duloxetine—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	9.96e-05	0.000308	CcSEcCtD
Duloxetine—Nausea—Abacavir—acquired immunodeficiency syndrome	9.92e-05	0.000307	CcSEcCtD
Duloxetine—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	9.9e-05	0.000307	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	9.89e-05	0.000306	CcSEcCtD
Duloxetine—Fatigue—Ritonavir—acquired immunodeficiency syndrome	9.88e-05	0.000306	CcSEcCtD
Duloxetine—Urticaria—Delavirdine—acquired immunodeficiency syndrome	9.84e-05	0.000305	CcSEcCtD
Duloxetine—Asthenia—Indinavir—acquired immunodeficiency syndrome	9.83e-05	0.000304	CcSEcCtD
Duloxetine—Somnolence—Saquinavir—acquired immunodeficiency syndrome	9.8e-05	0.000304	CcSEcCtD
Duloxetine—Pain—Ritonavir—acquired immunodeficiency syndrome	9.79e-05	0.000303	CcSEcCtD
Duloxetine—Constipation—Ritonavir—acquired immunodeficiency syndrome	9.79e-05	0.000303	CcSEcCtD
Duloxetine—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	9.79e-05	0.000303	CcSEcCtD
Duloxetine—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	9.79e-05	0.000303	CcSEcCtD
Duloxetine—Dizziness—Zidovudine—acquired immunodeficiency syndrome	9.74e-05	0.000302	CcSEcCtD
Duloxetine—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	9.7e-05	0.000301	CcSEcCtD
Duloxetine—Pruritus—Indinavir—acquired immunodeficiency syndrome	9.69e-05	0.0003	CcSEcCtD
Duloxetine—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	9.58e-05	0.000297	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	9.58e-05	0.000297	CcSEcCtD
Duloxetine—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	9.54e-05	0.000295	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	9.52e-05	0.000295	CcSEcCtD
Duloxetine—Insomnia—Lamivudine—acquired immunodeficiency syndrome	9.51e-05	0.000295	CcSEcCtD
Duloxetine—Fatigue—Saquinavir—acquired immunodeficiency syndrome	9.5e-05	0.000294	CcSEcCtD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	9.48e-05	0.00216	CbGpPWpGaD
Duloxetine—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	9.44e-05	0.000292	CcSEcCtD
Duloxetine—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	9.44e-05	0.000292	CcSEcCtD
Duloxetine—Pain—Saquinavir—acquired immunodeficiency syndrome	9.43e-05	0.000292	CcSEcCtD
Duloxetine—Constipation—Saquinavir—acquired immunodeficiency syndrome	9.43e-05	0.000292	CcSEcCtD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	9.41e-05	0.00214	CbGpPWpGaD
Duloxetine—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	9.37e-05	0.00029	CcSEcCtD
Duloxetine—Vomiting—Zidovudine—acquired immunodeficiency syndrome	9.37e-05	0.00029	CcSEcCtD
Duloxetine—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	9.37e-05	0.00029	CcSEcCtD
Duloxetine—Somnolence—Lamivudine—acquired immunodeficiency syndrome	9.35e-05	0.00029	CcSEcCtD
Duloxetine—HTR6—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	9.31e-05	0.00212	CbGpPWpGaD
Duloxetine—Rash—Zidovudine—acquired immunodeficiency syndrome	9.29e-05	0.000288	CcSEcCtD
Duloxetine—Asthenia—Efavirenz—acquired immunodeficiency syndrome	9.29e-05	0.000288	CcSEcCtD
Duloxetine—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	9.28e-05	0.000287	CcSEcCtD
Duloxetine—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	9.26e-05	0.000287	CcSEcCtD
Duloxetine—Headache—Zidovudine—acquired immunodeficiency syndrome	9.23e-05	0.000286	CcSEcCtD
Duloxetine—NPY1R—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	9.21e-05	0.0021	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	9.18e-05	0.00209	CbGpPWpGaD
Duloxetine—Pruritus—Efavirenz—acquired immunodeficiency syndrome	9.16e-05	0.000284	CcSEcCtD
Duloxetine—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	9.14e-05	0.000283	CcSEcCtD
Duloxetine—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	9.13e-05	0.000283	CcSEcCtD
Duloxetine—HTR2C—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	9.12e-05	0.00208	CbGpPWpGaD
Duloxetine—Urticaria—Ritonavir—acquired immunodeficiency syndrome	9.1e-05	0.000282	CcSEcCtD
Duloxetine—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	9.08e-05	0.000281	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	9.08e-05	0.000281	CcSEcCtD
Duloxetine—Fatigue—Lamivudine—acquired immunodeficiency syndrome	9.07e-05	0.000281	CcSEcCtD
Duloxetine—Dizziness—Indinavir—acquired immunodeficiency syndrome	9.06e-05	0.000281	CcSEcCtD
Duloxetine—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	9.05e-05	0.00028	CcSEcCtD
Duloxetine—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	9.05e-05	0.00028	CcSEcCtD
Duloxetine—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	9.01e-05	0.000279	CcSEcCtD
Duloxetine—Constipation—Lamivudine—acquired immunodeficiency syndrome	8.99e-05	0.000279	CcSEcCtD
Duloxetine—Pain—Lamivudine—acquired immunodeficiency syndrome	8.99e-05	0.000279	CcSEcCtD
Duloxetine—Asthenia—Delavirdine—acquired immunodeficiency syndrome	8.89e-05	0.000275	CcSEcCtD
Duloxetine—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	8.86e-05	0.000274	CcSEcCtD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	8.85e-05	0.00201	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	8.85e-05	0.00201	CbGpPWpGaD
Duloxetine—Pruritus—Delavirdine—acquired immunodeficiency syndrome	8.76e-05	0.000271	CcSEcCtD
Duloxetine—Urticaria—Saquinavir—acquired immunodeficiency syndrome	8.76e-05	0.000271	CcSEcCtD
Duloxetine—Nausea—Zidovudine—acquired immunodeficiency syndrome	8.75e-05	0.000271	CcSEcCtD
Duloxetine—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	8.71e-05	0.00027	CcSEcCtD
Duloxetine—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	8.71e-05	0.00027	CcSEcCtD
Duloxetine—Vomiting—Indinavir—acquired immunodeficiency syndrome	8.71e-05	0.00027	CcSEcCtD
Duloxetine—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	8.67e-05	0.000268	CcSEcCtD
Duloxetine—NPY1R—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	8.66e-05	0.00197	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	8.66e-05	0.00197	CbGpPWpGaD
Duloxetine—Rash—Indinavir—acquired immunodeficiency syndrome	8.64e-05	0.000268	CcSEcCtD
Duloxetine—Dermatitis—Indinavir—acquired immunodeficiency syndrome	8.63e-05	0.000267	CcSEcCtD
Duloxetine—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	8.6e-05	0.000266	CcSEcCtD
Duloxetine—Headache—Indinavir—acquired immunodeficiency syndrome	8.58e-05	0.000266	CcSEcCtD
Duloxetine—Dizziness—Efavirenz—acquired immunodeficiency syndrome	8.56e-05	0.000265	CcSEcCtD
Duloxetine—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	8.47e-05	0.000262	CcSEcCtD
Duloxetine—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	8.44e-05	0.000261	CcSEcCtD
Duloxetine—Urticaria—Lamivudine—acquired immunodeficiency syndrome	8.35e-05	0.000259	CcSEcCtD
Duloxetine—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	8.31e-05	0.000257	CcSEcCtD
Duloxetine—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	8.31e-05	0.000257	CcSEcCtD
Duloxetine—HTR2C—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	8.25e-05	0.00188	CbGpPWpGaD
Duloxetine—Vomiting—Efavirenz—acquired immunodeficiency syndrome	8.23e-05	0.000255	CcSEcCtD
Duloxetine—Asthenia—Ritonavir—acquired immunodeficiency syndrome	8.22e-05	0.000255	CcSEcCtD
Duloxetine—Dizziness—Delavirdine—acquired immunodeficiency syndrome	8.19e-05	0.000254	CcSEcCtD
Duloxetine—Rash—Efavirenz—acquired immunodeficiency syndrome	8.16e-05	0.000253	CcSEcCtD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	8.16e-05	0.00186	CbGpPWpGaD
Duloxetine—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	8.15e-05	0.000253	CcSEcCtD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	8.15e-05	0.00186	CbGpPWpGaD
Duloxetine—Nausea—Indinavir—acquired immunodeficiency syndrome	8.14e-05	0.000252	CcSEcCtD
Duloxetine—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	8.12e-05	0.000252	CcSEcCtD
Duloxetine—Headache—Efavirenz—acquired immunodeficiency syndrome	8.11e-05	0.000251	CcSEcCtD
Duloxetine—Pruritus—Ritonavir—acquired immunodeficiency syndrome	8.1e-05	0.000251	CcSEcCtD
Duloxetine—HTR6—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	8.01e-05	0.00182	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	7.92e-05	0.0018	CbGpPWpGaD
Duloxetine—Asthenia—Saquinavir—acquired immunodeficiency syndrome	7.91e-05	0.000245	CcSEcCtD
Duloxetine—Vomiting—Delavirdine—acquired immunodeficiency syndrome	7.88e-05	0.000244	CcSEcCtD
Duloxetine—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	7.84e-05	0.000243	CcSEcCtD
Duloxetine—Rash—Delavirdine—acquired immunodeficiency syndrome	7.81e-05	0.000242	CcSEcCtD
Duloxetine—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	7.8e-05	0.000242	CcSEcCtD
Duloxetine—Pruritus—Saquinavir—acquired immunodeficiency syndrome	7.8e-05	0.000242	CcSEcCtD
Duloxetine—Headache—Delavirdine—acquired immunodeficiency syndrome	7.76e-05	0.00024	CcSEcCtD
Duloxetine—HTR2C—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	7.76e-05	0.00177	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	7.76e-05	0.00177	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	7.75e-05	0.00176	CbGpPWpGaD
Duloxetine—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	7.75e-05	0.00024	CcSEcCtD
Duloxetine—Nausea—Efavirenz—acquired immunodeficiency syndrome	7.69e-05	0.000238	CcSEcCtD
Duloxetine—HTR2C—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	7.58e-05	0.00173	CbGpPWpGaD
Duloxetine—Dizziness—Ritonavir—acquired immunodeficiency syndrome	7.57e-05	0.000235	CcSEcCtD
Duloxetine—Asthenia—Lamivudine—acquired immunodeficiency syndrome	7.55e-05	0.000234	CcSEcCtD
Duloxetine—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	7.54e-05	0.000234	CcSEcCtD
Duloxetine—Pruritus—Lamivudine—acquired immunodeficiency syndrome	7.44e-05	0.00023	CcSEcCtD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	7.4e-05	0.00168	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	7.39e-05	0.00168	CbGpPWpGaD
Duloxetine—Nausea—Delavirdine—acquired immunodeficiency syndrome	7.36e-05	0.000228	CcSEcCtD
Duloxetine—Dizziness—Saquinavir—acquired immunodeficiency syndrome	7.29e-05	0.000226	CcSEcCtD
Duloxetine—Vomiting—Ritonavir—acquired immunodeficiency syndrome	7.28e-05	0.000226	CcSEcCtD
Duloxetine—Rash—Ritonavir—acquired immunodeficiency syndrome	7.22e-05	0.000224	CcSEcCtD
Duloxetine—HTR6—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	7.22e-05	0.00164	CbGpPWpGaD
Duloxetine—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	7.22e-05	0.000223	CcSEcCtD
Duloxetine—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	7.2e-05	0.000223	CcSEcCtD
Duloxetine—Headache—Ritonavir—acquired immunodeficiency syndrome	7.18e-05	0.000222	CcSEcCtD
Duloxetine—HTR2A—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	7.17e-05	0.00163	CbGpPWpGaD
Duloxetine—SLC6A2—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	7.16e-05	0.00163	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	7.08e-05	0.00161	CbGpPWpGaD
Duloxetine—Vomiting—Saquinavir—acquired immunodeficiency syndrome	7.01e-05	0.000217	CcSEcCtD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	6.98e-05	0.00159	CbGpPWpGaD
Duloxetine—Dizziness—Lamivudine—acquired immunodeficiency syndrome	6.95e-05	0.000215	CcSEcCtD
Duloxetine—Rash—Saquinavir—acquired immunodeficiency syndrome	6.95e-05	0.000215	CcSEcCtD
Duloxetine—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	6.94e-05	0.000215	CcSEcCtD
Duloxetine—Headache—Saquinavir—acquired immunodeficiency syndrome	6.91e-05	0.000214	CcSEcCtD
Duloxetine—HTR2C—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	6.85e-05	0.00156	CbGpPWpGaD
Duloxetine—Nausea—Ritonavir—acquired immunodeficiency syndrome	6.8e-05	0.000211	CcSEcCtD
Duloxetine—HTR2A—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	6.74e-05	0.00153	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	6.74e-05	0.00153	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	6.73e-05	0.00153	CbGpPWpGaD
Duloxetine—Vomiting—Lamivudine—acquired immunodeficiency syndrome	6.69e-05	0.000207	CcSEcCtD
Duloxetine—Rash—Lamivudine—acquired immunodeficiency syndrome	6.63e-05	0.000205	CcSEcCtD
Duloxetine—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	6.63e-05	0.000205	CcSEcCtD
Duloxetine—Headache—Lamivudine—acquired immunodeficiency syndrome	6.59e-05	0.000204	CcSEcCtD
Duloxetine—NPY1R—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.59e-05	0.0015	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	6.58e-05	0.0015	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	6.56e-05	0.00149	CbGpPWpGaD
Duloxetine—Nausea—Saquinavir—acquired immunodeficiency syndrome	6.55e-05	0.000203	CcSEcCtD
Duloxetine—NPY1R—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.49e-05	0.00148	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	6.42e-05	0.00146	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	6.39e-05	0.00146	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	6.36e-05	0.00145	CbGpPWpGaD
Duloxetine—SLC6A3—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	6.34e-05	0.00144	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	6.33e-05	0.00144	CbGpPWpGaD
Duloxetine—Nausea—Lamivudine—acquired immunodeficiency syndrome	6.25e-05	0.000193	CcSEcCtD
Duloxetine—HTR6—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	6.08e-05	0.00138	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	6.08e-05	0.00138	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	6.06e-05	0.00138	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	5.97e-05	0.00136	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	5.95e-05	0.00136	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	5.95e-05	0.00136	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	5.95e-05	0.00136	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	5.94e-05	0.00135	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	5.94e-05	0.00135	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.93e-05	0.00135	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	5.9e-05	0.00134	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	5.8e-05	0.00132	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	5.75e-05	0.00131	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	5.5e-05	0.00125	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	5.41e-05	0.00123	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	5.41e-05	0.00123	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	5.32e-05	0.00121	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	5.13e-05	0.00117	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	4.88e-05	0.00111	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.68e-05	0.00107	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.66e-05	0.00106	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	4.62e-05	0.00105	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	4.53e-05	0.00103	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.48e-05	0.00102	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.48e-05	0.00102	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	4.46e-05	0.00102	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	4.45e-05	0.00101	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.38e-05	0.000998	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.38e-05	0.000998	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.23e-05	0.000964	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	4.11e-05	0.000936	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	4.08e-05	0.000929	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.07e-05	0.000926	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	4.06e-05	0.000923	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	4.05e-05	0.000922	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.05e-05	0.000922	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.05e-05	0.000922	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.98e-05	0.000907	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.98e-05	0.000907	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.89e-05	0.000885	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.89e-05	0.000885	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.81e-05	0.000867	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.81e-05	0.000867	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.76e-05	0.000855	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.71e-05	0.000844	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.68e-05	0.000837	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	3.64e-05	0.000828	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	3.59e-05	0.000818	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.52e-05	0.000801	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.46e-05	0.000787	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.46e-05	0.000787	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	3.45e-05	0.000785	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—TAT—acquired immunodeficiency syndrome	3.44e-05	0.000782	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.43e-05	0.000781	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.41e-05	0.000777	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.4e-05	0.000773	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.34e-05	0.000759	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.29e-05	0.000748	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	3.22e-05	0.000734	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	3.2e-05	0.000729	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.19e-05	0.000727	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.19e-05	0.000727	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.03e-05	0.00069	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3e-05	0.000684	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.98e-05	0.000679	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	2.92e-05	0.000665	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.9e-05	0.000659	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.85e-05	0.00065	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	2.78e-05	0.000633	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.77e-05	0.00063	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.73e-05	0.000621	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.63e-05	0.000599	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.61e-05	0.000594	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.59e-05	0.00059	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.5e-05	0.00057	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.43e-05	0.000553	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.4e-05	0.000547	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.39e-05	0.000545	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.37e-05	0.00054	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.36e-05	0.000537	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.35e-05	0.000536	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.35e-05	0.000536	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.19e-05	0.000498	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.17e-05	0.000495	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.14e-05	0.000487	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.04e-05	0.000465	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.04e-05	0.000465	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.02e-05	0.000459	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.79e-05	0.000407	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.76e-05	0.000401	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.74e-05	0.000395	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.61e-05	0.000367	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.58e-05	0.000359	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.55e-05	0.000354	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.53e-05	0.000348	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.51e-05	0.000343	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.4e-05	0.000319	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.37e-05	0.000312	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.35e-05	0.000306	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.26e-05	0.000288	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.26e-05	0.000287	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.31e-06	0.000212	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.27e-06	0.000211	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.09e-06	0.000184	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	8.05e-06	0.000183	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.43e-06	0.000169	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	7.07e-06	0.000161	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	5.99e-06	0.000136	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.47e-06	0.000125	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.75e-06	0.000108	CbGpPWpGaD
